Zoetis Inc.

NYSE:ZTS

Drug Manufacturers - General

Healthcare
$85.55 +1.51%

+$1.17 today

Market cap
$34.76B
Beta
0.74
P/E (TTM)
12.5
EPS (TTM)
$6.26
Dividend yield
2.63%
52W Low $72.38High $161.77

Volume 4.66M

Average 6.20M

ZTS EBITDA Margin

EBITDA as a percentage of revenue.

Zoetis Inc.NYSE: ZTS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 42.4%

EBITDA Margin was 42.4% in Q2 FY2026, down 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 42.0%, down 1.1 pp year over year. Over 3 fiscal years it widened by 1.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 45.9% for the fiscal year ending Dec 2026, up from 43.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
42.4%+0.9 pp QoQ
Last fiscal yearDec 2025
43.0%+1.1 pp YoY
LTMJun 2026
42.0%-1.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.6 pp-2.9 pp-1.3 pp
1 year+1.1 pp+3.0 pp+1.8 pp
3 years+1.4 pp+0.9 pp-0.5 pp
5 years+10.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
43.0%
Year-over-year change
+1.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ZTS compares with its peers on the latest reported figures

  • ZTS's LTM Jun 2026 EBITDA Margin of 42.0% is the highest of the 6 companies compared; the peer median is 15.0%.
  • Its year-over-year change of -1.1 pp is the 4th highest of 6, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +1.4 pp compares with a peer median of +3.8 pp.
ZTS Competitors Peer median
EBITDA Margin for ZTS and competitors
Company Period LTM level YoY 3-year change
ZTSZoetis Inc.LTM Jun 202642.0% -1.1 pp+1.4 pp
IDXXIDEXX Laboratories, Inc.LTM Sep 202634.9% +0.0 pp+4.9 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
PAHCPhibro Animal Health CorporationLTM Mar 202615.0% +4.5 pp-1.1 pp
ELANElanco Animal Health IncorporatedLTM Sep 202613.2% -6.2 pp-5.3 pp
NEOGNeogen CorporationLTM Aug 202611.9% +111.0 pp+3.8 pp
Peer median (excluding ZTS) 15.0%+0.0 pp+3.8 pp

Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78B8.08B8.54B9.26B9.47B
Cost of Revenue2.46B2.6B2.71B2.86B2.79B
Gross Profit5.31B5.48B5.83B6.4B6.67B
Gross Margin68.3%67.8%68.3%69.1%70.5%
Research & Development508M539M614M686M698M
Selling, General & Admin2B2.01B2.15B2.32B2.38B
Operating Expenses2.51B2.55B2.77B3B3.08B
Depreciation & Amortization448M465M491M497M487M
EBITDA3.17B3.36B3.69B3.87B4.07B
EBITDA Margin40.8%41.6%43.1%41.8%43.0%
Operating Income2.8B2.93B3.07B3.39B3.6B
Operating Margin36.0%36.2%35.9%36.6%38.0%
Interest Income6M50M105M106M93M
Interest Expense236M237M258M242M243M
Other Income / Expenses(315M)(272M)(133M)(259M)(237M)
Income Before Tax2.49B2.66B2.94B3.13B3.36B
Pre-Tax Margin32.0%32.9%34.4%33.8%35.5%
Income Tax Expense454M545M596M637M687M
Net Income2.04B2.11B2.34B2.49B2.67B
Net Margin26.2%26.2%27.4%26.9%28.2%
EPS (Basic)4.294.515.085.476.03
EPS (Diluted)4.274.495.075.476.02
Weighted Avg Shares474.35M468.89M461.17M454.2M443.44M
Weighted Avg Shares (Diluted)476.72M470.39M462.27M454.85M443.84M

Zoetis Inc.

NYSE:ZTS

Intrinsic Alpha fair value

Locked

Current Price

$85.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.